Use of Proton-Pump Inhibitors and Risk of COVID-19 Infection

For UCSF Faculty and Staff: Please login via MyAccess to request access to update your Project.

Public Summary

Gastroesophageal reflux disease and the use of proton pump inhibitor medications are both widely prevalent in the population; they have both been mechanistically tied to the development of pneumonia in general but are not well understood as far as COVID-19 is concerned. More importantly, both GERD and PPI use may represent *reversible risk factors* for the development of COVID-19. We propose to use electronic health records data to establish an association between these two putative risk factors and the infection itself, in the hopes of identifying a modifiable risk factor that can reduce COVID19 susceptibility.